Kovack Advisors Inc. Has $1.22 Million Stock Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Kovack Advisors Inc. cut its holdings in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 1.8% in the 4th quarter, Holdings Channel reports. The firm owned 146,158 shares of the company’s stock after selling 2,644 shares during the period. Kovack Advisors Inc.’s holdings in Zevra Therapeutics were worth $1,219,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. FMR LLC grew its position in Zevra Therapeutics by 282,687.5% in the third quarter. FMR LLC now owns 2,313,202 shares of the company’s stock valued at $16,054,000 after acquiring an additional 2,312,384 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Zevra Therapeutics by 14.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock valued at $7,246,000 after purchasing an additional 129,600 shares in the last quarter. State Street Corp grew its holdings in shares of Zevra Therapeutics by 7.4% during the 3rd quarter. State Street Corp now owns 772,825 shares of the company’s stock valued at $5,363,000 after purchasing an additional 52,966 shares during the last quarter. Stonepine Capital Management LLC acquired a new position in Zevra Therapeutics during the 3rd quarter worth approximately $4,858,000. Finally, Vestal Point Capital LP bought a new position in Zevra Therapeutics in the 3rd quarter valued at approximately $3,644,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on ZVRA shares. Cantor Fitzgerald raised Zevra Therapeutics to a “strong-buy” rating in a report on Wednesday, January 29th. Guggenheim set a $21.00 price target on Zevra Therapeutics and gave the company a “buy” rating in a research note on Tuesday, February 4th. Canaccord Genuity Group lowered their price objective on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Zevra Therapeutics currently has an average rating of “Buy” and an average target price of $21.71.

Insider Activity at Zevra Therapeutics

In other news, CFO R. Laduane Clifton sold 11,000 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $86,460.00. Following the transaction, the chief financial officer now directly owns 51,361 shares of the company’s stock, valued at $403,697.46. The trade was a 17.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Neil F. Mcfarlane sold 61,273 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $481,605.78. Following the sale, the chief executive officer now owns 222,060 shares in the company, valued at approximately $1,745,391.60. The trade was a 21.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 85,773 shares of company stock worth $674,176 over the last quarter. Company insiders own 2.40% of the company’s stock.

Zevra Therapeutics Trading Up 5.4 %

NASDAQ:ZVRA opened at $7.79 on Friday. Zevra Therapeutics, Inc. has a 52 week low of $4.20 and a 52 week high of $9.76. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. The firm’s fifty day moving average is $8.07 and its 200-day moving average is $8.10. The firm has a market cap of $415.80 million, a P/E ratio of -3.95 and a beta of 2.00.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.